Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroimaging Biomarkers in Common Mental Disorders
NCT04218981Completed
- Sponsor
- Central South University
- Start
- Jan 2020
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label trial of olanzapine, risperidone, amisulpride, lithium, valproic acid and 1 more in schizophrenia, bipolar disorder (BD) and major depressive disorder (MDD) (4 arms), sponsored by Central South University. Primary endpoints: Resting-state functional magnetic resonance imaging at 8 weeks, Positive and Negative Syndrome Scale at 8 weeks and 3 more. Started Jan 2020; status: completed.
02
Drugs
olanzapinerisperidoneamisulpridelithiumvalproic acid
03
Conditions
schizophreniabipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04218981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218981.